SCHEMBL21050259

SCHEMBL21050259

C#C[C@@]1(CO)C[C@H](n2ccc3c(N)nc(Cl)nc32)C[C@H]1O

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 5/20 0.36
▸ HSP90B1 P14625 4/20 0.36
▸ HSP90AA1 P07900 2/20 0.36
▸ HTR2B P41595 1/20 0.35
▸ NT5E P21589 4/20 0.34
▸ PNP P00491 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ PDE3A Q14432 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.33
▸ ADORA2A P29274 4/20 0.32
▸ ADORA1 P30542 3/20 0.32
▸ TMEM97 Q5BJF2 1/20 0.32
▸ SIGMAR1 Q99720 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21050222 1.00 ADORA3 (0.36) ADORA3HSP90B1HSP90AA1HTR2BNT5E
SCHEMBL21050244 0.90 HTR2B (0.36) ADORA3HTR2BADORA1
SCHEMBL21050265 0.90 HTR2B (0.36) ADORA3HTR2BADORA1
SCHEMBL21050261 0.82 P2RY1 (0.46) NT5E
SCHEMBL21050245 0.82 P2RY1 (0.46) NT5E
SCHEMBL21050284 0.82 ADORA3 (0.54) ADORA3HSP90B1HSP90AA1NT5EPNP
SCHEMBL21050251 0.82 ADORA3 (0.54) ADORA3HSP90B1HSP90AA1NT5EPNP
Phosphoric Acid SCHEMBL21050262 0.80 NT5E (0.33) ADORA3HSP90B1HSP90AA1NT5EADORA2A
Phosphoric Acid SCHEMBL21050246 0.80 NT5E (0.33) ADORA3HSP90B1HSP90AA1NT5EADORA2A
SCHEMBL17106730 0.77 PDE4D (0.36) ADORA3HSP90B1HSP90AA1HTR2BNT5E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11040975-B2 Carbocyclic nucleoside reverse transcriptase inhibitors MERCK SHARP & DOHME CORP. (US) 2021-06-22 — — US claimed
US-20190177326-A1 CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2019-06-13 — — US claimed
US-11040975-B2 Carbocyclic nucleoside reverse transcriptase inhibitors MERCK SHARP & DOHME CORP. (US) 2021-06-22 — — US disclosed
US-20190177326-A1 CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2019-06-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11040975-B2 Carbocyclic nucleoside reverse transcriptase inhibitors SAMHD1, POLRMT, RNGTT ADORA3 712/4885HSP90B1 2250/4885HSP90AA1 2467/4885
US-20190177326-A1 CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS SAMHD1, POLRMT, RNGTT ADORA3 712/4885HSP90B1 2250/4885HSP90AA1 2467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback